目的　探讨非小细胞肺癌 (NSCL C)组织中谷胱甘肽 S-转移酶 π(GST- π)对含顺铂联合化疗方案疗效及生存期的影响。方法　 2 5例初诊初治行化疗的 NSCL C患者均接受含顺铂联合方案化疗 ,所用方案均 3～ 4周重复应用一次 ,至少用 2个周期。采用常规免疫组化 S- P法检测患者经支气管镜检所获取癌组织中 GST- π的表达。结果　 GST- π阳性表达率为 48.0 % (12 / 2 5 )。GST- π阴性表达组化疗有效率显著高于阳性组 (6 1.5 % vs16 .7% ,P=0 .0 414)。 GST- π阴性组中位生存期为 14个月 ,阳性组中位生存期为 11个月 ,两者之间无显著性差异。结论　NSCL C患者组织中 GST- π表达与其对含顺铂联合化疗方案的敏感性呈明显负相关 ,因此可作为预测化疗敏感性的有用指标。 Objective To investigate the effects of glutathione S-transferase π (GST-π) on the efficacy and survival of cisplatin combined chemotherapy in non-small cell lung cancer (NSCL C). Methods Twenty-five patients with newly diagnosed primary NSCLC underwent chemotherapy with cisplatin combined regimen. The regimens were repeated every 3 to 4 weeks for at least 2 cycles. The expression of GST-π in cancer tissues was detected by bronchoscopy with routine immunohistochemical S-P method. Results The positive rate of GST-π expression was 48.0% (12/25). The effective rate of chemotherapy in GST-π negative expression group was significantly higher than that in positive group (6 1.5% vs16.7%, P = 0.0144). The median survival was 14 months in the GST-π negative group and 11 months in the positive group, with no significant difference between the two. Conclusion The expression of GST-π in NSCL C patients is negatively correlated with the sensitivity of cisplatin-containing chemotherapy regimens. Therefore, GST-π expression can be used as a useful index in predicting chemosensitivity.